The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the ACVSB agreed the anti-HCV test was a major step forward in identifying those who could transmit the virus, but that routine screening should not commence until the FDA had granted a license and that a cost benefit appraisal should be conducted and discussed with the Department of Health.